Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Nov 5, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Stanford University
- Interventions being studied
- Radiation: Image-guided Radiation Therapy; Drug: Immunotherapy (physician's choice for standard of care immunotherapy)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Has stage IV non-small cell lung cancer, or initially stage I-III disease with distant metastatic recurrence 2. Age ≥ 18 3. Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks (refer to section 4.2.1) 4. Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after pre-immunotherapy baseline imaging. CT or PET/CT of at least chest/upper abdomen must be performed within 4 weeks prior to registration. For patients with history of brain metastases, brain MRI or CT is required within 4 weeks of registration; for other patients brain MRI or CT is required within 12 weeks of registration. Diagnostic PET/CT performed as part of radiation simulation can be used as the restaging imaging. 5. Most recent imaging shows measurable disease as defined by RECIST 1.1 6. Evaluation by a Stanford medical oncologist must show: 1. The patient is expected to continue on immunotherapy for at least three more months 2. Imaging must show response, stable disease, or modest progression 3. If there is modest progression, the patient must be clinically stable in terms of performance status and overall disease-related symptoms 7. Has at least one extracranial tumor safely treatable with radical-dose radiation therapy and that has not been previously treated with radiation 8. ECOG performance status 0-2 9. Has the ability to understand and the willingness to sign a written informed consent document.
- Untreated brain metastases, if not planned to be treated in this course of radiation therapy
- Pregnancy or women of childbearing potential not willing/able to use contraception during protocol treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University, School of MedicinePalo Alto, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 5, 2025. Always confirm current availability with the study team.